Webinar: Pediatric Dyslipidemias: Screening, Diagnosis, and Management in the Primary Care Setting (recorded live)
Jan. 2022Important Notices
"Watch the webinar recorded live May 19, 2021, where Brenda Mendizábal, MD, MS, Director of Pediatric Preventive Cardiology, UPMC Children’s Hospital of Pittsburgh, addresses improving the management of pediatric dyslipidemias.
During this hourlong session, Dr. Mendizábal discusses identifying children at greatest risk for accelerated atherosclerosis, formulating a plan for providing care to children with dyslipidemias, and the role of the pediatric preventive cardiologist.
Register or log in to listen to the webinar.
You may earn continuing medical education credits (CME) for watching this webinar.*
*This activity is approved for the following credit: AMA PRA Category 1 Credit™ and ANCC. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Provider is responsible for verifying CME eligibility."
During this hourlong session, Dr. Mendizábal discusses identifying children at greatest risk for accelerated atherosclerosis, formulating a plan for providing care to children with dyslipidemias, and the role of the pediatric preventive cardiologist.
Register or log in to listen to the webinar.
You may earn continuing medical education credits (CME) for watching this webinar.*
*This activity is approved for the following credit: AMA PRA Category 1 Credit™ and ANCC. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Provider is responsible for verifying CME eligibility."
Recent Announcements
Medicaid Renewal
Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.Aug. 2026Important Notices
Provider Directory Updates and Required Attestation
As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).Aug. 2026Important Notices
Voluntary nationwide recall: Tyenne (Fresenius – August 2026)
Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.Aug. 2026Pharmacy Updates